You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Mass. movers

Piper analyst bullish on Infinity’s drug

Shares of Cambridge-based Infinity Pharmaceuticals Inc. rose after Piper Jaffray analyst M. Ian Somaiya said he believes the company’s experimental drug, IPI-145, will be approved to treat several types of cancer, with annual sales eventually approaching $3 billion. Infinity’s other drug, IPI-504, is in clinical testing as a treatment for lung cancer. The company is scheduled to report its fourth-quarter results on Tuesday. Analysts forecast a quarterly loss of 84 cents per share.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week